We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+2.89%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.86B
AUM Growth
+$29.2M
Cap. Flow
+$147M
Cap. Flow %
5.13%
Top 10 Hldgs %
48.59%
Holding
107
New
12
Increased
2
Reduced
2
Closed
19

Top Buys

Rank Stock Value
1
TYRA icon
Tyra Biosciences
TYRA
+$121M
2
TNGX icon
Tango Therapeutics
TNGX
+$82.4M
3
BPMC
Blueprint Medicines
BPMC
+$39.6M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$37.4M
5
NUVL
Nuvalent
NUVL
+$35.1M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$63.2M
2
AMRN
Amarin Corp
AMRN
+$26.3M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$24M
4
AGEN
Agenus
AGEN
+$22M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$20.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.15%
2 Financials 0.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PSTX
101
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
– –
-1,251,055
Closed -$12.5M
CERE
102
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-714,500
Closed -$18.3M
CBAY
103
DELISTED
Cymabay Therapeutics
CBAY
– –
-4,000,000
Closed -$17.4M
SGEN
104
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-400,000
Closed -$63.2M
KDMN
105
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-6,205,882
Closed -$24M
CHFW.U
106
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
– –
-200,000
Closed -$2.04M
ZGNX
107
DELISTED
Zogenix, Inc.
ZGNX
– –
-27,300
Closed -$472K
1 2 3 4
5

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Boxer Capital held 107 positions worth $2.86B, up 1% from $2.83B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Boxer Capital deployed $147M of net new capital in Q3 2021, opening 12 new positions and adding to 2 existing holdings. Its largest new stake was Tyra Biosciences: 6,323,359 shares worth $111M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Solid Biosciences, an estimated $1.42M trimmed.

  • Boxer Capital's largest Q3 2021 buy was Tyra Biosciences: 6,323,359 shares worth $111M.
  • Boxer Capital added most to Kinnate Biopharma Inc. Common Stock in Q3 2021, an estimated $17M increase.
  • Boxer Capital's biggest Q3 2021 reduction was Solid Biosciences, cutting an estimated $1.42M.
  • Boxer Capital fully exited Seagen Inc. Common Stock in Q3 2021, selling an estimated $63.2M.
  • Boxer Capital's ten largest holdings make up 49% of its $2.86B portfolio in Q3 2021.
  • Boxer Capital opened 12 new positions and closed 19 in Q3 2021.
  • Boxer Capital's portfolio value rose 1% quarter-over-quarter to $2.86B.

Based on Boxer Capital's 13F filing for Q3 2021, filed 15 Nov 2021.